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A b s t r a c t
Introduction: The aim of the study was to present the experience of Polish 
centers regarding dual therapy based on the integrase inhibitor raltegra-
vir (RAL) and ritonavir-boosted protease inhibitors (PI/r) for treating treat-
ment-naïve and -experienced HIV-infected patients.
Material and methods: The paper concerns a  retrospective multicenter 
study. The medical databases of six main Polish HIV centers from January 
2009 to December 2014 were analyzed for the use of combined antiretro-
viral treatment consisting of RAL + PI/r. This study included 126 HIV-infect-
ed patients receiving RAL + PI/r therapy, of whom 17 patients were treat-
ment-naive and 109 patients were treatment-experienced.
Results: In treatment-experienced patients, the most common reasons for 
the introduction of a RAL + PI/r regimen were virologic failure and impaired 
renal function (45 of 109 patients). In the treatment-naïve group kidney dis-
ease was the cause of the RAL + PI/r regimen in 3 of 17 participants. In 
treatment-experienced patients, 80% of individuals still were on RAL + PI/r 
treatment after 12 months, 65% after 24 months and 53% of subjects after 
60 months. In both groups, the simplification of the antiretroviral regimen 
was the most common reason for discontinuation of RAL + PI/r based therapy.
Conclusions: In antiretroviral-experienced patients the dual therapy based 
on RAL + PI/s is safe and effective. In antiretroviral-naïve patients the RAL + 
PI/r regimen is rarely used in Poland.
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Introduction
Since combined antiretroviral therapy was introduced in 1996, huge 
progress has been made in this field. At the moment, over 30 antiretro-
viral drugs belonging to five main classes are available on the market, to 
limit HIV replication and progression of the disease [1]. 
Both Polish and international recommendations define the standard 
antiretroviral regimen as a combination of different drugs. The long expe-
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rience and established efficacy of regimens based 
on nucleoside and nucleotide reverse-transcriptase 
inhibitors justify their use as a  main component 
of each drug combination [1–3]. However, antiret-
roviral regimens incorporating these drugs are not 
suitable for all patients. The main side effect of the 
nucleoside reverse-transcriptase inhibitors is mito-
chondrial toxicity, whereas the use of nucleotide 
reverse-transcriptase inhibitor has been associat-
ed with greater reductions in bone mineral density 
(osteopenia, osteoporosis) and renal toxicity [4–7]. 
In comparison to treatment-naïve HIV-infected pa-
tients, treatment-experienced patients are a diffi-
cult-to-treat group of subjects, in whom previous 
changes of drugs have narrowed the treatment op-
tions. Although great progress has been made in 
this field, new therapeutic options are still needed, 
and further collection of the experiences of the use 
of nonstandard therapies is extremely important. 
The aim of this retrospective multicenter study 
was to present data on the use of dual therapy 
consisting of integrase inhibitor raltegravir (RAL) 
with ritonavir-boosted protease inhibitors (PI/r) 
in treatment-naïve and treatment-experienced 
HIV-infected patients. 
Material and methods
The medical databases of six Polish HIV centers 
(Warsaw, Krakow, Wroclaw, Lodz, Szczecin, Chor-
zow) from January 2009 to December 2014 were 
analyzed for the use of combined antiretroviral 
treatment consisting of RAL and PI/r. During this 
period, a group of 126 patients receiving at least 
one dose of study drugs was enrolled in the study. 
No exclusion criteria were used to enable the eval-
uation of dual therapy in a real-world setting. Data 
were collected from the introduction of dual ther-
apy based on RAL + PI/r to the last follow-up visit.
The authors addressed the following questions: 
What was the reason for the introduction of the 
dual therapy? What was the reason for discontin-
uation of the dual therapy? How long did the pa-
tients remain on this therapy?
The safety of therapy was measured as the 
number of patients discontinuing the therapy due 
to an adverse event.
In experienced patients, the efficacy was mea-
sured as the percentage of patients remaining 
free of therapeutic failure evaluated by a time to 
treatment failure algorithm. A Kaplan-Meier time-
to-event method was used to determine the rate 
of “survival”. 
Missing data and discontinuation of therapy for 
any reason were considered as treatment failure.
The study was approved by the ethics com-
mittee of the Medical University of Lodz. Written 
informed  consent  was obtained from all partici-
pants of the study.
Statistical analysis
The Kaplan-Meier survival analysis was used, 
whereas stopping RAL + PI/r treatment was taken 
as the primary end point. 
Results
This retrospective study included 126 HIV-infect-
ed patients receiving RAL + PI/r therapy, of whom 
17 patients were treatment-naive and 109 were 
treatment-experienced. The group comprised 
92 males (76 in the treatment-experienced and 16 in 
the treatment-naive group) and 34 females (33 in the 
treatment-experienced and 1 in the treatment-na-
ive group), with a median age of 42 years. The main 
route of HIV transmission in the study group was ho-
mosexual/bisexual contact. In the treatment-experi-
enced group, before switching to RAL + PI/r, 19 pa-
tients were on non-nucleoside reverse-transcriptase 
inhibitor based regimen, 11 on an integrase inhibitor 
based regimen and 79 on a PI based regimen.
The median duration of RAL + PI/r therapy was 
60 weeks (mean: 87 weeks). The characteristics of 
the patients are presented in Table I.
Reasons for introduction of RAL + PI/r 
treatment 
In treatment-experienced patients the most 
common reasons for introduction of the RAL + PI/r 
regimen were virologic failure and impaired renal 
function. For 14 treatment-naïve patients, the rea-
sons for starting the RAL + PI/r regimen were not 
established, but in 3 participants it was kidney 
disease. All these reasons are presented in Table II.
Reasons for discontinuation of RAL + PI/r 
treatment 
In 88 out of 126 patients, the treatment with 
RAL+PI/r was ongoing, while it had been ended in 
38 patients (32 treatment-experienced patients and 
6 treatment-naïve patients). In both groups, the most 
common reason for discontinuation of RAL + PI/r 
based therapy was the simplification of the antiret-
roviral regimen. All reasons given for discontinuation 
of the antiretroviral regimen are presented in Table III.
Survival in treatment-naive  
and treatment-experienced patients
Survival in the treatment-naive group is pre-
sented in Figure 1. In experienced patients, 80% 
of subjects still were on RAL + PI/r treatment after 
12 months, 65% after 24 months and 53% of sub-
jects after 60 months (Figure 2). 
Discussion
Antiretroviral therapy has substantially im-
proved the life expectancy of HIV-infected pa-
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Table I. Characteristics of study group
Variable Treatment-experienced patients Treatment-naïve patients
n % n %
Men 76 69.7 16 94.1
Route of HIV 
transmission
Intravenous drug users 35 32.1 1 5.9
Hetero 22 20.2 3 17.6
Ho/Bi 41 37.6 7 41.2
Other/unknown 11 10.1 6 35.3
Regimens RAL/DRV/r 65 59.5 15 88.2
RAL/ATV/r 22 20.2 1 5.9
RAL/LPV/r 17 15.6 0 0
RAL/SQV/r 5 4.6 1 5.9
Median LQ-UQ Median LQ-UQ
Age at the moment of HIV infection 33 26–40 28 27–33
CD4 at the moment of HIV infection 278 130–494 334 243–495
CD4 nadir 133 57–230 318.5 140.5–387
Age at the moment of introduction of PI/RAL 43 36–50 32 29–39
Duration of antiretroviral therapy before 
the introduction of PI/InI [weeks]
62 40–129.4 0
Number of antiretroviral regimens before 
the introduction  of RAL/PI/r
3 2–5 0
Table II. Reasons for introduction of RAL + PI/r treatment
Reason Treatment-experienced patients
N = 109
Treatment-naïve patients
N = 17
n % n %
Unknown 11 10.1 14 82.4
Osteoporosis 2 1.8 0 0
Renal dysfunction 20 18.3 3 17.6
Gastrointestinal disorders 7 6.4 0 0
Virologic failure 25 22.9 0 0
Hematologic disorders 5 4.6 0 0
Hypersensitivity 3 2.8 0 0
Simplification of therapy 12 11.0 0 0
Immunologic failure 1 0.9 0 0
Lipoatrophia 3 2.8 0 0
Lipid disorders 5 4.6 0 0
Acidosis 1 0.9 0 0
Polyneuropathy 1 0.9 0 0
Drug interactions 2 1.8 0 0
Intolerance 11 10.1 0 0
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tients. Nowadays, opportunistic infections are 
observed far less frequently [8–10]. However, the 
antiretroviral therapy must be continued for the 
rest of the patient’s life. Although current antiret-
roviral regimens are generally safe and well toler-
ated, they are not devoid of serious side effects 
[5, 7, 11–14]. Therefore the evaluation of available 
antiretroviral regimens provides new options for 
HIV-infected patients and allows their therapy to 
be individualized. The aim of the present work 
was to summarize the clinical experiences on ral-
tegravir-containing regimens in combination with 
boosted protease inhibitors in patients from 6 Pol-
ish HIV treatment centers.
However, the Polish experience in the treat-
ment of antiretroviral-naïve patients with RAL + 
PI/r is sparse, because such therapy has only been 
applied in 17 patients. It is worth noting that im-
paired renal function was given as the reason for 
the introduction of RAL + PI/r therapy in 3 patients, 
 0 12 24 36 48
Time [months]
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 17 9 4 4 2
Figure 1. Survival with no treatment failure (treat-
ment-naive group)
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No. of patients
 109 70 41 23 13 8 4
Figure 2. Survival with no treatment failure (treat-
ment-experienced group)
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Table III. Reasons for discontinuation of RAL + PI/r treatment 
Reason Treatment-experienced
N = 109
First-line regimen
N = 17
n % n %
Simplification of therapy 16 14.7 3 17.6
Adherence/lost to follow up 3 2.8 2 11.8
Kidney dysfunction 0 0 1 5.9
Pancreatitis 1 0.9 0 0
Bowel disorders 1 0.9 0 0
Immunologic failure 1 0.9 0 0
Rash 1 0.9 0 0
Other 3 2.8 0 0
Mental disorders 1 0.9 0 0
Death not associated with ARV 
treatment
2 1.8 0 0
Lack of improvement of lipid 
parameters and bilirubin
1 0.9 0 0
Lipid disorders 1 0.9 0 0
Virologic failure 0 0 0 0
Myalgia 1 0.9 0 0
Total 32 29.4 6 35.3
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while no such information was given by the other 
patients. It is possible that the introduction of dual 
therapy in this group of patients is so rare due to 
the results of several studies which indicate that 
regimens containing RAL + PI/r were not found to 
be as effective as treatment based on PI + 2NRTI/r 
[15–17]. Therefore, in Polish and international 
guidelines, dual therapy remains an alternative 
regimen in treatment-naïve HIV-patients [2, 3].
The majority of patients enrolled to this study 
(109) were administered dual therapy as consec-
utive treatment. In this group, 80% of patients 
still received RAL + PI/r after 12 months of treat-
ment, while this number had fallen to 65% after 
24 months. Our results are consistent with other 
studies concerning the safety and tolerability of 
the RAL + PI/r regimen in treatment-experienced 
patients. A  study by Harness on virologically sup-
pressed HIV patients who had been switched from 
a triple-drug regimen to RAL + ATV/r found that HIV 
viremia was still undetectable in 69.4% of patients 
48 weeks after switching to the dual regimen [18]. 
In the SECOND-LINE study [15], where RAL + LPV/r 
was applied after failing the first-line regimen based 
on non-NRTI and 2N(t)RTI, 80.4% of patients were 
found to have an HIV viral load below 200 copies/ml 
after 96 weeks. It is important to note that, contrary 
to the SECOND-LINE study, the majority of patients 
in the present study received more antiretroviral 
regimens before the introduction RAL/PI/r. 
In conclusion, our findings indicate that in 
antiretroviral-experienced patients dual therapy 
based on RAL + PI/ r is safe and effective. In anti-
retroviral-naïve patients the RAL+PI/r regimen is 
rarely used in Poland. 
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